Biopharma cold chain will hit $2.58 bn: FedEx APAC VP

In terms of flexibility, biopharma supply chains will continue to be optimised on an individual level, and every shipper will have access to a personalised command centre to monitor disruptions in the supply chain, with a new level of near-molecular precision. This level of data will also mean greater security throughout the supply chain.

This flexibility will also extend to a venerable fundamental of the supply chain - consolidation. In 2013, most shipments are consolidated, packed in containers in the belly of an aircraft or hull of a ship or back of a truck.

By 2033, pharma shippers will have the flexibility of removing a portion, or even a single item, from a consolidated shipment. It will provide the ability to expedite the customisation and delivery of a biopharma drug instead of sending it with dozens of other packages on the back of a truck.